Business
BioSpectrum Asia
"We'll focus on genomic medicine and growing our business in China"
In May 2023, Cytiva and the life sciences business of Pall Corporation completed their integration and are now united as one business under the Cytiva brand. Emmanuel Ligner, President and CEO, Cytiva and Danaher Group Executive shares some pertinent details with BioSpectrum Asia about the merger, including the strategic rationale behind the decision, the impact on employees, customers, and stakeholders. Ligner reveals the long-term vision and goals for the newly-merged company. Edited excerpts:
3 min |
BioSpectrum Asia June 2023
BioSpectrum Asia
Turning Microbiome Therapy into Modern Panacea
The United States Food and Drug Administration’s (US FDA) approval of Seres Therapeutics’ (USA) VOWST in April 2023 and Ferring Pharmaceuticals’ (Switzerland) REBYOTA in November 2022, has marked a pivotal moment in the microbiome therapeutics landscape. There are many disease areas with significant unmet medical needs that are linked to the state of an individual’s microbiome. In recent years, there has been growing interest and research in the field of microbiome therapies. Researchers are exploring the potential of manipulating the microbiome to prevent, treat, or manage a wide range of health issues, including gastrointestinal disorders, metabolic disorders, autoimmune diseases, and neurological disorders. Let’s explore this new era of microbiome therapeutics and challenges in developing such therapies.
4 min |
BioSpectrum Asia June 2023
BioSpectrum Asia
Can India's National Medical Devices Policy Unleash Sector's Full Potential?
The National Medical Devices Policy, 2023 that got the approval of the government of India on April 26 seems to have made the medical devices sector happy. The slew of strategies mentioned in the policy assures a win–win outcome for the manufacturers as well as patients. Experts are upbeat about the projected growth of the sector in the near future. The policy aims to bring a range of interventions in a coherent manner that would facilitate focussed and efficient support and facilitation for the sector by the respective agencies. Let’s explore further.
8 min |
BioSpectrum Asia June 2023
BioSpectrum Asia
Waters Corp launches next generation Xevo TQ Absolute IVD mass spectrometer
Waters Corporation has unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications
1 min |
May 2023
BioSpectrum Asia
BD introduces advanced ultrasound technology for optimal IV placement
BD (Becton, Dickinson and Company), a leading global medical technology company based in the US, has launched a new, easy-to-use advanced ultrasound device with a specialised probe designed to provide clinicians with optimal IV placement
1 min |
May 2023
BioSpectrum Asia
Korea designs artificial kidney for early detection of drug toxicity
A research team from Pohang University of Science and Technology (POSTECH), in South Korea, has engineered an artificial kidney that allows for the early detection of adverse drug reactions
1 min |
May 2023
BioSpectrum Asia
India develops screening device to assess blood vessel health
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed a novel, non-invasive device to assess the health and age of blood vessels and thereby provide early screening for cardiovascular diseases
1 min |
May 2023
BioSpectrum Asia
International dementia research collaboration to address key health challenge in Australia and Japan
Three expert teams in Australia will share $1.5 million to undertake research into causes of dementia through projects funded by the National Health and Medical Research Council (NHMRC)
1 min |
May 2023
BioSpectrum Asia
Sydney University strengthens international ties in research and innovation
New international opportunities are open to Sydney researchers and students as the University expands partnership agreements with the University of Glasgow, Scotland and the University of California San Diego, US
1 min |
May 2023
BioSpectrum Asia
WHO certifies Azerbaijan and Tajikistan as malaria-free
The World Health Organisation (WHO) has certified Azerbaijan and Tajikistan for achieving elimination of malaria in their territories
1 min |
May 2023
BioSpectrum Asia
Fujitsu launches new cloud-based platform for healthcare in Japan
Fujitsu has announced the launch of a new cloud-based platform that allows users to securely collect and leverage health-related data to promote digital transformation in the medical field
1 min |
May 2023
BioSpectrum Asia
Takeda to invest ¥100 B in new facility for plasma-derived therapies in Japan
Takeda Pharmaceutical will invest approximately 100 billion yen (Y) to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan
1 min |
May 2023
BioSpectrum Asia
Singapore gives nod to first smart wearable stethoscope
Aevice Health, a Singapore-based medtech startup that specialises in developing remote respiratory monitoring solutions, has announced that its flagship medical device, the AeviceMD Monitoring System, has received approval from the Health Sciences Authority of Singapore (HSA).
1 min |
May 2023
BioSpectrum Asia
Australia announces world first framework for rural and remote nursing
A world-first guide addressing the unique demands and challenges for Registered Nurses in rural and regional Australia has been released
1 min |
May 2023
BioSpectrum Asia
India exempts full customs duty on all drugs used in rare diseases treatment
The Government of India has given full exemption from basic customs duty on all drugs and food for special medical purposes imported for personal use for treatment of all rare diseases listed under the National Policy for Rare Diseases 2021 through a general exemption notification
1 min |
May 2023
BioSpectrum Asia
$15B Pharma R&D Spends ROCKS APAC
Earlier seen as a generic powerhouse, Asia is now an important hub for pharma R&D innovation
10+ min |
May 2023
BioSpectrum Asia
The Key To A Precision Medicine Future: AI Plus Human Ingenuity
Artificial intelligence (AI) is being used to find new promising targets and design new molecules to treat diseases. It is also being applied in the optimisation of the clinical trial process – analysing data to predict outcomes to help prevent timely and costly late-stage failures, and producing health digital twins to speed up trials, and precision public health. It’s very possible to imagine a data-driven, streamlined, precision medicine future merging the best of human and machine intelligence to manage our individual health in ways we never previously imagined.
5 min |
BioSpectrum Asia April 2023
BioSpectrum Asia
"Immutep has started exploring the potential of the first ever triple combination therapy with Eftilagimod"
Australian firm Immutep has partnered with Merck and Pfizer for a new Phase I clinical study in patients with urothelial cancer for its lead product candidate -eftilagimod, in combination with avelumab (BAVENCIO).
2 min |
BioSpectrum Asia April 2023
BioSpectrum Asia
"APAC continues to be a global hub for clinical trials"
The Asia Pacific (APAC) represents more than a third of all cell and gene therapy in global trials.
5 min |
BioSpectrum Asia April 2023
BioSpectrum Asia
Addressing 'Orphaning' of Rare Diseases
To tackle any disease requires sustained research and development (R&D), to help us learn more about it and to create effective treatments. However, when it comes to R&D around rare diseases, there are few key challenges which ultimately impact patient outcomes.
2 min |
BioSpectrum Asia April 2023
BioSpectrum Asia
"India is now working on the target of ending TB by 2025"
Noting the declining number of Tuberculosis (TB) patients, India resolved to eliminate TB by 2025 as against the global target of 2030.
5 min |
BioSpectrum Asia April 2023
BioSpectrum Asia
A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
10+ min |
BioSpectrum Asia April 2023
BioSpectrum Asia
Scientists In New Zealand Identify Drug That Could Extend Lifespan
The age-old quest for immortality has taken a step forward with the results of a New Zealand study recently published by the researchers at the University of Auckland.
1 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
How Plausible Is Ending TB Scourge?
Despite countries making bold commitments to end TB by 2030, in the Sustainable Development Goals, the WHO End TB Strategy and the 2018 political declaration on the fight against TB, the epidemic shows no sign of slowing down.
10 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
Can Med Tourism Industry Hit Goldmine With Robot-Assisted Surgery?
The quality of Healthcare is projected to become enhanced in the future, aided by new innovations in technology.
10+ min |
BioSpectrum Asia March 2023
BioSpectrum Asia
Sciex expands protein characterisation capabilities
Sciex, a US-based leader in life science analytical technologies, has announced the launch of the Fast Glycan Labeling and Analysis kit for quantitative glycan analysis and an update for Biologics Explorer software to enhance critical protein therapeutic analysis workflows.
1 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
Korea designs smart contact lens for diagnosing and treating glaucoma
A research team at Pohang University of Science and Technology (POSTECH) in South Korea has developed a smart contact lens by combining an intraocular pressure (IOP) sensor and a flexible drug delivery system to manage IOP measurement and medication administration in glaucoma patients.
1 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
World Health Organisation releases new Global Breast Cancer Initiative Framework
The World Health Organisation (WHO) has released a new Global Breast Cancer Initiative Framework providing a roadmap to attain the targets to save 2.5 million lives from breast cancer by 2040.
1 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
CEPI collaborates to advance tools for Sudan ebolavirus vaccine research
The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting the development of an international antibody standard against Sudan ebolavirus (SUDV)
1 min |
BioSpectrum Asia March 2023
BioSpectrum Asia
Global Fund provides $867M in additional funding for pandemic preparedness and response
Since December 2022, the Global Fund has awarded $547 million in additional funding to 40 countries through its COVID-19 Response Mechanism (C19RM) and has now initiated the process to award a further $320 million, making a total of approximately $867 million.
1 min |